References
- Bergquist A, Ljungquist A, Moberger G. Classification of bladder tumours based on the cellular pattern. Acta Chir Scand 1985; 130: 371–378
- Bluestone J A, Matis L A. TCR gamma/delta cells —minor redundant T cell subset or specialized immune system component. J Immunol 1989; 142: 1785–1788
- Böyum A. Isolation of leukocytes from human blood. Scand J Clin Lab Invest 1968; 21(Suppl 97)77–89
- Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, Donner J. Established cell line of urinary bladder carcinoma (T24) containing tumour‐specific antigen. Int J Cancer 1983; 11: 765–773
- Bubenik J, Kieler J, Tromholt V, Hermann G, Jandlova T. Defect in lectin‐induced interleukin 2 production by peripheral blood lymphocytes of patients with invasive urinary bladder carcinoma. Immunol Lett 1988; 18: 115–118
- Christensen B, Kieler J, Vilien M, Don P, Wang C Y, Wolf H. A classification of human urothelial cells propagated in vitro. Anticancer Res 1984; 4: 319–338
- Droller M J. Biologic response modifiers in genitourinary neoplasia. Cancer 1987; 60: 635–644
- Haaff E O, Catalona J, Latliff T L. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 1986; 136: 970–974
- Hemler M E, Jacobson J G, Brenner M B, Mann D, Strominger J L. VLA‐I, a T cell surface antigen which defines a novel late stage of human T cell activation. Eur J Immunol 1985; 15: 502–508
- Hermann G G, Petersen K R, Steven K, Zeuthen J. Reduced LAK‐cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: Decreased LAK‐cytotoxicity caused by a low incidence of CD56 + and CD57+ mononuclear cells. J Clin Immunol 1990; 10: 311–320
- Herr H W, Laudone V P, Whitmore W F. An overview of intravesical therapy for superficial bladder tumors. J Urol 1987; 138: 1363–1368
- Herr H W, Pinsky C M, Whitmore W F, Oettgen H F, Melamed M R. Effect of intravesical bacillus calmette‐guerin (BCG) on carcinoma in situ of the bladder. Cancer 1983; 51: 1323–1326
- Koga S, Sakuragi T, Taniguch M, Nishikido S, Kubota T, Sakuragi T, Shindo K, Saitoh Y. BCG induced killer cell activity. Urol Res 1988; 16: 351–355
- Meijden A P M, Steerenberg P A, Hoogstraten I M W, Kerckhaert J A, Schreinemachers L M H, Harthoorn‐Lasthuizen E J, Hagenaars A M, de Jong W H, Debruyne F M J, Ruitenberg E J. Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with Bacillus Calmette‐Guerin. Cancer Immunol Immunother 1989; 28: 287–295
- Peuchmaur M, Benoit G, Viellefond A, Chevalier A, Lemaigre G, Martin E D, Jardin A. Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical Bacillus Calmette‐Guerin. Urol Res 1989; 17: 299–303
- Vilien M, Christensen B, Wolf H, Rasmussen F, Hou‐Jensen C, Povlsen C O. Comparative studies of normal, “spontaneously” transformed and malignant human urothelium cells in vitro. Eur J Cancer Clin Oncol 1983; 19: 775–789